Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2019-03-19 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
收购“宜春悦康吉泰医药有限公司”100%股权的补充公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the acquisition of 100% equity in a company named 宜春悦康吉泰医药有限公司 by 昆药集团股份有限公司. It includes transaction details, parties involved, financial data, evaluation reports, and payment terms. The document is not a financial report like an annual or interim report, nor is it a simple announcement of a report publication. It is a corporate announcement about a capital transaction involving acquisition of shares, with detailed terms and financial implications. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as acquisitions. The document length (5361 characters) and content confirm it is a full announcement, not just a brief notice or regulatory filing. Therefore, the appropriate classification is CAP with high confidence.
2019-03-19 Chinese
公司章程
Governance Information Classification · 100% confidence The document is titled '昆药集团股份有限公司章程' which translates to 'Articles of Association of KPC Pharmaceuticals, Inc.' It contains detailed chapters on company governance, shareholder rights, board structure, share issuance, share repurchase, and other corporate governance matters. The content is a comprehensive set of internal rules and regulations governing the company’s organization and behavior, including shareholder meetings, board of directors, management, and financial accounting systems. There is no indication that this is an announcement, a financial report, or a meeting presentation. It is a governance document outlining the company's internal rules and governance practices. Therefore, the document fits the category of Governance Information (CGR). The document length is substantial (15,000 characters), indicating it is the full text of the governance document, not a brief announcement or summary.
2019-03-15 Chinese
收购“宜春悦康吉泰医药有限公司”100%股权的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the acquisition of 100% equity in a company named 宜春悦康吉泰医药有限公司 by 昆药集团股份有限公司. It details the investment project overview, the target company's situation, the impact on the listed company, and investment risks. The document is a formal announcement of a transaction related to acquisition of shares, including financial details and agreements. It is not a full annual or interim report, nor a call transcript or audit report. It is not a proxy statement or voting result. The content fits best under Capital/Financing Update (CAP) as it concerns acquisition and investment activities affecting the company's capital structure and business operations. The document length is short (1485 characters), but it contains substantive information about the acquisition, not just a notice of report publication or certification. Therefore, the appropriate classification is CAP with high confidence.
2019-03-15 Chinese
收购西藏藏药（集团）利众院生物科技有限公司15%股权的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the acquisition of a 15% equity stake in a subsidiary company by the listed company. It details the transaction, shareholding changes, financial figures of the target company, and the impact and risks related to the acquisition. There is no indication that this is a full financial report, audit, or earnings release. It is a capital transaction update related to shareholding and ownership structure. Therefore, the document fits best under Capital/Financing Update (CAP). The document length is short and it is not merely announcing a report publication, so it is not RPA or RNS.
2019-03-15 Chinese
九届六次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of Kunming Pharmaceutical Group Co., Ltd. It details specific board decisions including acquisitions, amendments to company bylaws, and asset write-offs. The document includes voting results and references to other related announcements but does not contain financial statements or detailed financial analysis. It is clearly a Board/Management Information announcement about board resolutions and decisions rather than a full report or financial disclosure.
2019-03-15 Chinese
关于修订公司章程的公告
Governance Information Classification · 95% confidence The document is a detailed announcement regarding amendments to the company's articles of association (公司章程) in response to changes in laws and regulations such as the Company Law and the Listing Company Governance Guidelines issued by the China Securities Regulatory Commission. It includes specific clauses and their modifications, governance practices, shareholder rights, board responsibilities, and procedural rules for shareholder meetings. The content is focused on governance structure and internal rules rather than financial results or audit opinions. It is not a financial report, earnings release, or audit report. It is not a simple announcement of a report publication but a substantive governance document. Therefore, the document fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2019-03-15 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.